Printer Friendly

Kyowa Hakko Kirin Co., Ltd., - Kyowa Kirin Presents Post-Hoc Analysis of Pivotal Trial for Poteligeo[R] (mogamulizumab-kpkc) -- 3/6/2019.

TOKYO, June 3, 2019/PRNewswire/ -- Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces that a post-hoc analysis of the MAVORIC trial (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) is being presented today at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO).

MAVORIC is the first pivotal trial in cutaneous T-cell lymphoma (CTCL) to use progression free survival (PFS) as a primary endpoint. (1) In the Phase 3 trial, 372 adult patients with previously treated mycosis fungoides (MF) or Sezary syndrome (SS) stages IB to IV were randomized to either mogamulizumab (1 mg/kg dosed once weekly for the first 5 infusions, then once every 2 weeks) or vorinostat, dosed per prescribing information. (1) Patients were treated until disease progression in any compartment (skin, blood, lymph, or viscera) or unacceptable toxicity. Mean PFS was 7.6 vs 3.1 months with mogamulizumab vs vorinostat, respectively, P<0.001. (1)

The study being presented at ASCO examined time to next treatment in patients with MF and SS to further explore the patient clinical experience. For this analysis, time to next treatment was defined as time to any therapy excluding topical steroids or focal radiation. In MF and SS, time to next treatment represents an additional measure of clinical benefit and disease control in patients who may have progressed based on strict protocol definitions of progression. (2)

The median time to next treatment for the full population of MAVORIC was longer with mogamulizumab at 11 months (95% CI, 8.8-12.6) compared to vorinostat at 3.5 months. (2) Median time to next treatment was also longer for patients treated with mogamulizumab versus vorinostat across disease stage grouping (IB/II: mogamulizumab, n=68, 7.0 months [4.9-10.1] vs. vorinostat n=72, 3.3 months [2.8-4.9]; lll/IV: mogamulizumab, n=118,12.9 months [10.6-16.7] vs. vorinostat n=114, 3.5 months [2.8-4.7]) or by disease type (MF: mogamulizumab, n=105, 8.8 months [6.1-11.55] vs. vorinostat, n=99, 4.1 months [3.1-5.2]; SS: mogamulizumab, n=81, 12.9 months [10.7-16.7] vs. vorinostat, n=87, 3.3 months [2.6-3.8]). (2)

"Cutaneous T-cell lymphomas like mycosis fungoides and Sezary syndrome are chronic skin malignancies characterized by relapsing and remitting behavior and progressive resistance to treatments. They are slow to progress and may require many lines of systemic therapy over the disease course," said Jeffrey S. Humphrey, M.D., President and Chief Medical Officer of Kyowa Kirin Pharmaceutical Development, Inc. "The data from this analysis further underscores the potential benefit of Poteligeo for patients living with these rare and serious diseases who have had at least one systemic therapy."

Poteligeo is approved in the United States for the treatment of adult patients with relapsed or refractory MF or SS after at least one prior systemic therapy. MF and SS are the most common subtypes of CTCL. (3)

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

Please see Poteligeo indication and Important Safety Information below.

INDICATION

POTELIGEO[R] (mogamulizumab-kpkc) injection, for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy. Important Safety Information

Warnings and Precautions:

* Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).

* Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction.

* Infections: Monitor patients for signs and symptoms of infection and treat promptly.

* Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.

* Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.

Adverse Reactions:

* The most common adverse reactions (reported in [greater than or equal to] 10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).

About Kyowa Kirin

Kyowa Hakko Kirin Co., Ltd. is a research-based life sciences company, with special strengths in biotechnologies. In the core therapeutic areas of oncology, nephrology and immunology/allergy, Kyowa Hakko Kirin leverages leading-edge biotechnologies centered on antibody technologies, to continually discover innovative new drugs and to develop and market those drugs world-wide. In this way, the company is working to realize its vision of becoming a Japan-based global specialty pharmaceutical company that contributes to the health and wellbeing of people around the world. Kyowa Kirin International PLC is a wholly owned subsidiary of Kyowa Hakko Kirin and is a rapidly growing specialty pharmaceutical company engaged in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in Europe and the United States. Kyowa Kirin International is headquartered in Scotland. You can learn more about the business at: www.kyowa-kirin.com.

About mogamulizumab

Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4), which is frequently expressed on leukemic cells of certain hematologic malignancies including CTCL (cutaneous T-cell lymphoma). (4)

About mycosis fungoides (MF) and Sezary Syndrome (SS)

MF and SS are the two most common subtypes of CTCL, a rare type of non-Hodgkin's lymphoma, which is characterized by localization of malignant T lymphocytes to the skin, and depending on the stage, the disease may involve skin, blood, lymph nodes, and viscera. (3)

About MAVORIC

MAVORIC is a Phase 3 open-label, multi-center, randomized study of mogamulizumab versus vorinostat in patients with MF and SS who have failed at least one prior systemic treatment. (1) The study was conducted in the U.S., Europe, Japanand Australia, and randomized 372 patients to receive either mogamulizumab or vorinostat. (1)

https://www.prnewswire.com/news-releases/kyowa-kirin-presents-post-hoc-analysis-of-pivotal-trial-for-poteligeo-mogamulizumab-kpkc-300860349.html
COPYRIGHT 2019 Acquisdata Pty Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Media Releases
Publication:Japan Pharmaceutical
Date:Jun 11, 2019
Words:1125
Previous Article:Astellas Pharma Inc. - Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent...
Next Article:Chugai Pharmaceutical Co., Ltd - Chugai Files for Additional Indication of ALK Inhibitor ALECENSA for Recurrent or Refractory ALK Fusion...
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters